Literature DB >> 10937543

Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.

L Han1, M Cole, F Bellavance, J McCusker, F Primeau.   

Abstract

OBJECTIVES: To estimate the annual rate of change scores (ARC) on the Mini-Mental State Examination (MMSE) in Alzheimer's disease (AD) and to identify study or population characteristics that may affect the ARC estimation.
METHODS: MEDLINE was searched for articles published from January 1981 to November 1997 using the following keywords: AD and longitudinal study or prognosis or cognitive decline. The bibliographies of review articles and relevant papers were searched for additional references. All retrieved articles were screened to meet the following inclusion criteria: (a) original study; (b) addressed cognitive decline or prognosis or course of AD; (c) published in English; (d) study population included AD patients with ascertainable sample size; (e) used either clinical or pathological diagnostic criteria; (f) longitudinal study design; and (g) used the MMSE as one of the outcome measures. Data were systematically abstracted from the included studies, and a random effects regression model was employed to synthesize relevant data across studies and to evaluate the effects of study methodology on ARC estimation and its effect size.
RESULTS: Of the 439 studies screened, 43 met all the inclusion criteria. After 6 studies with inadequate or overlapping data were excluded, 37 studies involving 3,492 AD patients followed over an average of 2 years were included in the meta-analysis. The pooled estimate of ARC was 3.3 (95% confidence interval [CI]: 2.9-3.7). The observed variability in ARC across studies could not be explained with the covariates we studied, whereas part of the variability in the effect size of ARC could be explained by the minimum MMSE score at entry and number of assessments.
CONCLUSIONS: A pooled average estimate of ARC in AD patients was 3.3 points (95% CI: 2.9-3.7) on the MMSE. Significant heterogeneity of ARC estimates existed across the studies and cannot be explained by the study or population characteristics investigated. Effect size of ARC was related to the initial MMSE score of the study population and the number of assessments.

Entities:  

Mesh:

Year:  2000        PMID: 10937543     DOI: 10.1017/s1041610200006359

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  41 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

3.  Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.

Authors:  P J Connelly; N P Prentice; K G Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

4.  Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Authors:  JoAnn T Tschanz; Chris D Corcoran; Sarah Schwartz; Katherine Treiber; Robert C Green; Maria C Norton; Michelle M Mielke; Kathleen Piercy; Martin Steinberg; Peter V Rabins; Jeanne-Marie Leoutsakos; Kathleen A Welsh-Bohmer; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2011-06       Impact factor: 4.105

Review 5.  Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

Authors:  David B Hogan
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

6.  Cognitive Aging Trajectories and Burdens of Disability, Hospitalization and Nursing Home Admission Among Community-living Older Persons.

Authors:  Ling Han; Thomas M Gill; Bobby L Jones; Heather G Allore
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-10-28       Impact factor: 6.053

7.  Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease.

Authors:  George S Vlachos; George P Paraskevas; Dimitris Naoumis; Elizabeth Kapaki
Journal:  J Neural Transm (Vienna)       Date:  2012-03-30       Impact factor: 3.575

8.  The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderly.

Authors:  Elizabeth Guerrero-Berroa; Xiaodong Luo; James Schmeidler; Michael A Rapp; Karen Dahlman; Hillel T Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Int J Geriatr Psychiatry       Date:  2009-12       Impact factor: 3.485

9.  Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

Authors:  Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen
Journal:  Lancet Neurol       Date:  2013-01-31       Impact factor: 44.182

10.  Risk Factors Associated With Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia Patients.

Authors:  Eric Jutkowitz; Richard F MacLehose; Joseph E Gaugler; Bryan Dowd; Karen M Kuntz; Robert L Kane
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-04-29       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.